These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34202919)

  • 1. Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.
    Nijen Twilhaar MK; Czentner L; van Nostrum CF; Storm G; den Haan JMM
    Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34202919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine approaches for antigen capture by liposomes.
    Zhou S; Luo Y; Lovell JF
    Expert Rev Vaccines; 2023; 22(1):1022-1040. PubMed ID: 37878481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal adjuvant development for leishmaniasis vaccines.
    Askarizadeh A; Jaafari MR; Khamesipour A; Badiee A
    Ther Adv Vaccines; 2017 Aug; 5(4-5):85-101. PubMed ID: 29201374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing liposomal adjuvants for the next generation of vaccines.
    Perrie Y; Crofts F; Devitt A; Griffiths HR; Kastner E; Nadella V
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):85-96. PubMed ID: 26576719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal presentation of antigens for human vaccines.
    Glück R
    Pharm Biotechnol; 1995; 6():325-45. PubMed ID: 7551224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licensed liposomal vaccines and adjuvants in the antigen delivery system.
    Krasnopolsky Y; Pylypenko D
    BioTechnologia (Pozn); 2022; 103(4):409-423. PubMed ID: 36685697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
    Watson DS; Endsley AN; Huang L
    Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
    Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
    Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer.
    Firdaus FZ; Bartlett S; Hussein WM; Lu L; Wright Q; Huang W; Nahar UJ; Yang J; Khongkow M; Veitch M; Koirala P; Ruktanonchai UR; Monteiro MJ; Gonzalez Cruz JL; Stephenson RJ; Wells JW; Toth I; Skwarczynski M
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy.
    Yu R; Mai Y; Zhao Y; Hou Y; Liu Y; Yang J
    J Drug Target; 2019 Aug; 27(7):780-789. PubMed ID: 30589361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of surface-linked liposomal antigens for the development of vaccines].
    Uchida T; Taneichi M
    Nihon Rinsho; 2008 Oct; 66(10):1894-902. PubMed ID: 18939487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.
    De Serrano LO; Burkhart DJ
    J Nanobiotechnology; 2017 Nov; 15(1):83. PubMed ID: 29149896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates.
    Laing P; Bacon A; McCormack B; Gregoriadis G; Frisch B; Schuber F
    J Liposome Res; 2006; 16(3):229-35. PubMed ID: 16952877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.
    Alving CR
    Ann N Y Acad Sci; 1995 May; 754():143-52. PubMed ID: 7625648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MANα1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1.
    Kornuta CA; Bidart JE; Soria I; Gammella M; Quattrocchi V; Pappalardo JS; Salmaso S; Torchilin VP; Cheuquepán Valenzuela F; Hecker YP; Moore DP; Zamorano PI; Langellotti CA
    Transbound Emerg Dis; 2021 Mar; 68(2):587-597. PubMed ID: 32643286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.